Janssen Biotech, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$123Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
106,291clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Tremfya $61M associated (2023-2025)
- Stelara $11M associated (2023-2025)
- Simponi Aria $9.4M associated (2023-2025)
- Rybrevant $9.3M associated (2023-2025)
- Carvykti $8.6M associated (2023-2025)
- Erleada $5.9M associated (2023-2025)
- Tecvayli $5.3M associated (2023-2025)
- Darzalex $5.1M associated (2023-2025)
- Akeega $2.4M associated (2023-2025)
- Simponi $1.4M associated (2023-2025)
- Talvey $1.2M associated (2023-2025)
- Imbruvica $955K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Scott Sellinger | Tallahassee, FL | Urology | $585,085.25 |
| Mahdi Taha | Boca Raton, FL | Medical Oncology | $554,815.27 |
| Rhonda Hewitt | Stanford, CA | Nurse Practitioner | $450,583.50 |
| David Waterhouse | Cincinnati, OH | Hematology & Oncology | $430,871.02 |
| Ruemu Birhiray | Indianapolis, IN | Hematology & Oncology | $429,304.34 |
| Rafat Abonour | Indianapolis, IN | Hematology (Internal Medicine) | $377,065.57 |
| Steven Feldman | Winston Salem, NC | Dermatology | $370,352.27 |
| Henry Fung | Philadelphia, PA | Hematology & Oncology | $367,109.55 |
| Reeli Reinu | Maitland, FL | Physician Assistant | $353,274.03 |
| Nicole Seminara | Huntersville, NC | Dermatology | $350,971.41 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.